---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-000863"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:20:58.717217+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "medium"
source: SEC EDGAR
---

# Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded

## Summary
- Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.
- PPX autologous product revenue increased by approximately $474,000 in FY2024 compared to prior fiscal year.
- Issued patents for amniotic fluid processing techniques and PPX blood-derived exosome pain treatment method in past year.
- Strategic partnership with Physicians Group LLC, operating 75 clinics and 750 clinicians, for collaborative research and clinical trials.
- Launched ZEO HAIR GROW topical product with Exotropin; aims at hair loss market affecting 35M men and 31M women in US.

## SEC filing metadata
- accession: 0001829126-25-000863
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/0001829126-25-000863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-000863
- JSON: https://secwatch.observer/filing/0001829126-25-000863.json
- Plain text: https://secwatch.observer/filing/0001829126-25-000863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.